Lumosa Board Approved the Binding Term Sheet for
LT1001, a Long-acting Analgesic Injection, with a
Pakistani Pharmaceutical Company
Date of events
2022/08/09
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/08/09
2.Company name:Lumosa Therapeutics Co., Ltd.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:not applicable
5.Cause of occurrence:
Lumosa board approved the binding term sheet for LT1001, a long-acting
analgesic injection, with a Pakistani pharmaceutical company where the
counterparty will be granted exclusive rights to market, sell, promote and
distribute LT1001 in Pakistan. Lumosa will be responsible for supplying
LT1001 to the company.
6.Countermeasures:not required
7.Any other matters that need to be specified:
(1)The name of the partner is not disclosed at the present time as the
execution process has yet been completed by both sides.
(2)Taiwan Ministry of Science and Technology and National Defense Medical
Center licensed the exclusive development and commercialization rights
and relevant technologies of LT1001 to Lumosa. In turn, Lumosa shall
pay 20% of considerations from the sub-license fee to the licensor, as
well as 1.875%~3.75% royalty from the sales of LT1001 long-acting
analgesic injection.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lumosa Therapeutics Co. Ltd. published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 10:05:04 UTC.
LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.
LUMOSA THERAPEUTICS CO., LTD. 
